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Estrogens circulate at concentrations less than 20 pg/mL in men and postmenopausal women, presenting
analytical challenges. Quantitation by immunoassay is unreliable at these low concentrations. Liquid
chromatography tandem mass spectrometry (LC–MS/MS) offers greater speciﬁcity and sometimes
greater sensitivity, but ionization of estrogens is inefﬁcient. Introduction of charged moieties may en-
hance ionization, but many such derivatives of estrogens generate non-speciﬁc product ions originating
from the “reagent” group. Therefore an approach generating derivatives with product ions speciﬁc to
individual estrogens was sought.
Estrogens were extracted from human plasma and serum using solid phase extraction and derivatized
using 2-ﬂuoro-1-methylpyridinium-p-toluenesulfonate (FMP-TS). Electrospray in positive mode with
multiple reaction monitoring using a QTrap 5500 mass spectrometer was used to quantify “FMP” deri-
vatives of estrogens, following LC separation.
Transitions for the FMP derivatives of estrone (E1) and estradiol (E2) were compound speciﬁc (m/z
362-238 and m/z 364-128, respectively). The limits of detection and quantitation were 0.2 pg on-
column and the method was linear from 1–400 pg/sample. Measures of intra- and inter-assay variability,
precision and accuracy were acceptable (o20%). The derivatives were stable over 24 h at 10 °C (7–9%
degradation). Using this approach, E1 and E2, respectively were detected in human plasma and serum:
pre-menopausal female serum (0.5 mL) 135–473, 193–722 pmol/L; male plasma (1 mL) 25–111, 60–
180 pmol/L and post-menopausal female plasma (2 mL), 22–78, 29–50 pmol/L.
Thus FMP derivatization, in conjunction with LC–MS/MS, is suitable for quantitative analysis of es-
trogens in low abundance in plasma and serum, offering advantages in speciﬁcity over immunoassay and
existing MS techniques.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).r B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Analysis of endogenous estrogens is challenging due to their
extremely low concentrations, e.g. estradiol (E2) can circulate in
concentrations less than 20 pg/mL. Concentrations are commonly
o50 pg/mL (o184 pmol/L) in men [1] and 2–21 pg/mL (7–
77 pmol/L) in postmenopausal women [2]. Moreover their levels
reduce with age and in some diseases such as cardiovascular dis-
ease [3] and type 2 diabetes mellitus [4]. Although immunoassays
have been widely used to quantify across the range of circulating
concentrations of estrone (E1; 55–740 pmol/L) [1] and estradiol
(E2; 118–915 pmol/L) [5], speciﬁcity is challenging due to inter-
ference from endogenous isomers and other steroids in the bio-
logical matrix [6]. In addition, none of the commercial methods
have satisfactory sensitivity and selectivity for use in older female
subjects, in whom concentrations are lower [6–8].
Liquid chromatography–mass spectrometry (LC–MS) provides
an alternative analytical method of high speciﬁcity and indeed is
already replacing immunoassays in the analysis of other steroids
routinely monitored in clinical practice, e.g. testosterone and cor-
tisol [6]. However, even with tandem MS coupled to ultra high
performance liquid chromatography (UHPLC) [7,8], estrogens are
often present in concentrations below the limit of detection of
analysis in human plasma and serum, particularly in samples from
post-menopausal women [9].
While ultra-sensitive methods have been developed using
state-of-the art tandem MS [10], derivatization improves sensi-
tivity by endowing the analyte with a chargeable or permanently
charged group for analysis by MS, changing efﬁciency of ioniza-
tion, fragmentation and retention [6,11]. LC–MS methods have
been reported to measure underivatized and derivatized estro-
gens, with the latter demonstrating improved limits of quantita-
tion (LOQs): for example LOQs of underivatized steroids (E1; 15,
E2; 20 pg/mL) [1] versus those of derivatized steroids (E1; 1, E2;
0.5 pg/mL) [2]. Endogenous estrogens have ketone, hydroxyl and
phenolic functional groups suitable for targeting by derivatization
reagents.
Previous derivatization reagents employed include dansyl
chloride [11–16], pyridine-3-sulfonyl chloride [17,18], 4-(1H-pyr-
azol-1-yl)benzenesulfonyl chloride [17], N-methyl-nicotinic acid
N-hydroxysuccinimide ester [19] and isomers of 1,2-dimethylimi-
dazole-sulfonyl chloride [17,20]. Reaction of the phenolic hydroxyl
with a secondary amine moiety of dansyl chloride via nucleophilic
aromatic substitution has been the most common approach [11–
16], but a disadvantage for tandem MS is that the product ion is
generated by the derivative moiety and hence is not speciﬁc for
the analyte by mass. In particular the natural massþ2 isotopomers
of estrone may generate a background signal within the mass
transition of the estradiol derivative [12].
Some of these problems can be averted by chromatographic
separation but confounding interference can still arise from un-
known estrogen metabolites or from stable isotope labeled es-
trogens used as in vivo tracers or internal standards. Therefore a
derivative generating analyte-speciﬁc precursor and product ions
is desirable to improve speciﬁcity [6,13,17,20] and permit more
rapid chromatography. This may be achieved by using 2-ﬂuoro-1-
methylpyridinium-p-toluenesulfonate (FMP-TS) (Fig. 1), which has
been used previously to detect estrogens in water [13] and human
and bovine serum [21].
We aimed to establish an analytical approach using a methyl-
pyridinium derivative of estrogens to detect these hormones in
low abundance in human plasma and, in particular, to evaluate if
the approach could quantify circulating steroids in post-meno-
pausal females. A highly sensitive method was validated using ion-
exchange solid phase extraction, in conjunction with LC–MS/MS.2. Materials and methods
2.1. Standards and solvents
Estrone (E1), 17β-estradiol (E2), 17α-estradiol (17αE2), formic acid
(FA; Z98%), triethylamine (TEA; Z99.5%) and 2-ﬂuoro-1-methylpyr-
idinium-p-toluenesulfonate (FMP-TS) were from Sigma-Aldrich, Inc.
(St. Louis, USA). 3,4-[13C]2-estrone (13C2E1), 2,4,16,16-[2H]4-estrone
(95-97%) (d4E1), 3,4-[13C]2-estradiol (13C2E2) and
2,4,16,16-[2H]4-estradiol (d4E2) were from Cambridge Isotope labora-
tories Inc. (Andover, USA). HPLC grade glass distilled solvents (me-
thanol, acetone, hexane and water) were from Fisher Scientiﬁc UK
Limited (Leicestershire, UK).
2.2. Instrumentation
Structural elucidation of derivatives of steroids in solutions of
high concentration was performed on a LC triple quadrupole mass
spectrometer, a TSQ Quantum Discovery MS (Thermoﬁsher, Wal-
tham, USA) and operated using Xcalibur software version 2.0.
Conﬁrmation of accurate mass was performed by direct infusion
into a 12 T SolariX dual source Fourier Transform Ion Cyclotron
Resonance MS (FT-ICR MS; Bruker Daltonics, MA, US), operated
with SolariX control v1.5.0 (build 42.8) software. High-sensitivity
quantiﬁcation was performed on a QTrap 5500 (AB Sciex, War-
rington, UK) coupled to an Acquity™ Ultra Performance LC (Wa-
ters Corporation, Milford, USA), operated using Analyst software
v1.5.1.
2.3. Plasma and serum samples
Male and female human plasma and post-menopausal female
human serum for method development and validation were from
TCS Biosciences (Buckingham, UK), stored at 20 °C. This was
prepared from human blood from healthy donors in approved
blood collection centers. Plasma was collected into anticoagulant
(citrate phosphate dextrose adenine), whereas serum was col-
lected without anticoagulant and allowed to clot naturally.
For method application, serum was collected from 27 pre-me-
nopausal women undergoing investigations for menstrual dis-
orders (24–52 years old); these patient samples were anonymised
prior to analysis and ethical approval was thus not required for
this method development study. Further plasma samples were
obtained from subjects participating in experimental medicine
studies for which local ethical approval had been obtained; 20
post-menopausal women (58–60 years old) and 48 men (21–85
years old) men [22].
2.4. Standard solutions
Estrogens and internal standards (IS; 5 mg) were dissolved in
acetone (5 mL) and stored at 20 °C. Working solutions (1 pg/mL
to 100 mg/mL) were prepared by serial dilution on the day of use.
2.5. Generation of FMP derivatives
FMP-TS (50 mL; 5 mg/mL in acetonitrile, containing TEA (1%))
was freshly prepared prior to reaction and added to the standard/
extract. The mixture was vortexed (10 s) then incubated (40 °C,
15 min). Mobile phase (water: methanol 65:35), containing FA
(0.1%, 50 mL) was added to quench the reaction.
2.6. Fragmentation analysis of FMP derivatives of estrogens
For product ion characterization by tandem MS at nominal
mass, molecular ions of derivatives were isolated by Q1 and
Table 1
Optimized tuning conditions for analysis of methylpyridinium derivatives of estrogens.
Analyte Precursor ion m/z Product ions m/z Collision energy (V) Collision cell exit potential (V) De-clustering potential (V) Entrance potential (V)
E1 362 238* 57 10 136 10
252$ 57 10
E2 364 128* 19 18 51 10
110$ 39 10
13C2E1 364 240* 55 10 61 10
254$ 57 12
13C2E2 366 130* 63 28 76 10
110$ 59 12
d4E1 366 240* 59 22 81 10
254$ 57 24
d4E2 368 130* 39 14 56 10
111$ 23 10
Voltage (V); estrone (E1); estradiol (E2); 3,4-[13C]2-estrone (13C2E1); 2,4,16,16-[2H]4-estrone (d4E1); 3,4-[13C]2-estradiol (13C2E2); 2,4,16,16-[2H]4-estradiol (d4E2); quantiﬁer
(*) and qualiﬁer ($).
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Fig. 1. Formation of methylpyridinium ether derivative of phenolic estrogens, showing an example of derivatization of an estrogen with 2-ﬂuoro-1-methylpyridiniump-
toluenesulfonate (FMP-TS) in the presence of triethylamine (TEA).
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55 eV E2). Q3 was operated in scanning mode from m/z 100 to m/z
50 above the mass of the molecular ion under analysis. Conditions
for multiple reactions monitoring (MRM) were optimized by au-
totuning during infusion of solutions of the E1 and E2 derivatives
(50 ng/mL). Collision energy was optimized to achieve suitable
fragmentation for each transition.
For structural elucidation by FTICR-MS, ions of accurate mass
(m/z 200–1500) were isolated for 20 s prior to CID experiments at
37 eV.
2.7. MS tuning of derivatives for quantitiation
MRM conditions for estrogen FMP derivatives were tuned by
infusion using a QTrap 5500 mass spectrometer, operated in po-
sitive ion electrospray ionization (ESI) mode. Estrogen FMP deri-
vatives (1 mg/mL) were diluted 1:10 in mobile phase (water: me-
thanol 65:35), containing FA (0.1%). Precursor ions for the deri-
vatives were selected; m/z 362 for E1 and m/z 364 for E2 and
17αE2 (a naturally occurring isomer). Optimized conditions
achieving maximal sensitivity for detection of quantiﬁer and
qualiﬁer ions are given in Table 1, and were used in conjunction
with curtain gas (25 mTorr), collision gas (medium), ion spray
(5500 V), temperature (600 °C), ion gas 1 (45) and ion gas 2
(20 mTorr).
2.8. Chromatographic conditions
Chromatographic conditions were optimized using an Acquity
UPLCs BEH C18 column (502.1 mm 1.7 mm Waters Corporation,
Milford, USA). An isocratic solvent system of water: methanol
(65:35), containing FA (0.1%, 0.4 mL/min) was diverted to waste for
the initial 2 minutes and maintained for a further 6 min followedby a rapid gradient executed over 2 min until ﬁnal conditions of
water: methanol (5:95), containing FA (0.1%) (0.4 mL/min) were
achieved. The column and autosampler temperatures were 25 °C
and 10 °C, respectively. Injection volume was usually 20 mL in
partial loop mode with needle overﬁll.
2.9. Extraction method
Aliquots of pre-menopausal female serum (0.5 mL), post-me-
nopausal female plasma (2 mL) and male plasma (1 mL) were
subject to centrifugation for 20 minutes (8000 g, 4 °C) and sedi-
ment removed. The sample volumes were adjusted to 2 mL with
water and internal standards (200 pg) added. Solid-phase extrac-
tion using Oasiss MCX (3 cc/60 mg, Waters) extraction cartridges
was performed under gravity. Prior to loading the sample (2 mL),
the cartridges were conditioned with methanol (2 mL), followed
by water (2 mL). The sample was loaded and allowed to pass
through the cartridges and the eluate discarded. Next, the car-
tridges were washed with FA (2% v/v, 2 mL) and again the eluate
discarded. Finally, the steroids were eluted in methanol (2 mL).
Extracts were reduced to dryness under oxygen-free nitrogen
(40 °C) and the residues were derivatized as above.
2.10. Assay validation
2.10.1. Optimization of derivatization conditions
Reaction conditions were optimized ﬁrst using aqueous ex-
tracts and then extracts of plasma. Conditions evaluated were in-
cubation temperature (25–70 °C), time (5–60 min), reaction vo-
lume (25–250 mL) and FMP-TS concentration (0.1–10 mg/mL).
2.10.2. Extraction efﬁciency
Recoveries of IS from water and plasma were assessed by
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ples pre- and post-spiked with IS (200 pg; n¼6). Mean peak areas
of derivatives following extraction in pre-spiked samples were
divided by those in post-spiked samples and expressed as a
percentage.
2.10.3. Assessment of ion suppression
Ion suppression of signal of estrogenic derivatives in the pre-
sence of extracts of plasma was evaluated by comparing signal
intensity of IS (200 pg) post-spiked into extracted plasma with
that of aqueous IS solutions of the same concentration (n¼6).
Mean peak areas of derivatives of steroids from post-spiked ex-
tracted plasma was divided by mean peak areas of unextracted
standards and expressed as a percentage.
2.10.4. Speciﬁcity
Mass chromatograms were inspected at the retention times of
analytes and IS for possible interferences by other endogenous
compounds in plasma, such as 17αE2. The ratio of quantiﬁer to
qualiﬁer ions of each analyte of IS were measured in extracts from
plasma and compared with those of standards and accepted if
within 20%.
2.10.5. Limit of detection (LOD)
Estrogens (100, 10, 1 ng and 100, 10, 1, 0.1 pg/sample) were
analysed by LC–MS/MS and the Signal/Noise (SNR) calculated from
peak areas of steroids and adjacent background noise (over the
same time window as the peak width). The LOD was assigned as a
SNR 3.
2.10.6. Linearity
Blank samples and aliquots containing estrogens (1, 2.5, 5, 10,
25, 50, 100, 200, 400 pg/sample) and internal standards (200 pg)
were analysed by LC–MS/MS. Calibration curves were plotted as
the peak area ratio (standard/IS) versus amount of estrogens. Ca-
libration lines of best ﬁt were acceptable if the regression coefﬁ-
cient, r, was 40.99. Weightings of 1, 1/x and 1/x2 were compared.
2.10.7. Limit of quantitation (LOQ)
Replicate aliquots (100, 10, 1 ng and 100, 10, 1, 0.1 pg/sample;
n¼6) of estrogens and internal standards were prepared as above
and analysed. The LOQ was calculated as that amount affording
precision and accuracy of 20% or less.
2.10.8. Accuracy and precision
Injector reproducibility was tested by injecting the same extracts of
male and female plasma 6 times on the same day. The intra- and inter-
assay precision and accuracy were assessed using 6 samples (1, 50 and
400 pg/sample) prepared on the same day and different days, re-
spectively, alongside a standard curve (n¼6). The precision was cal-
culated as the Relative Standard Deviation (RSD) (standard deviation/
mean100), and % accuracy was the Relative Mean Error (RME)
((measured valuetheoretical value)100).
2.10.9. Stability
Stability following storage in the auto-sampler (10 °C) was
evaluated by reinjection of a calibration curve and plasma sample
after 24 h. The effects of short-term storage in the freezer (20
and 80 °C) on sample integrity were assessed by reinjection
after 24 h and 48 h and 28 days storage.
2.11. Method application
Estradiol and estrone were quantiﬁed in human serum or
plasma from pre and post-menopausal females and males using
the validated approach.3. Results and discussion
3.1. Method development
3.1.1. Development of derivatization approach
The anticipated reaction is shown in Fig. 1, yielding a positively
charged derivative. More intense signals from ions were measured
with ESI compared with atmospheric pressure chemical ionization
(APCI), typical of species with pre-existing charge. In contrast APCI
is often the method of choice for underivatized steroids, due to
their low proton/electron capture afﬁnities in liquid-phase [6]. The
precursor ions of the derivatives of estrone and estradiol were the
expected molecular ions, m/z 362 and 364, respectively. However,
after CID experiments, product ion spectra of E1 FMP and E2 FMP
differed from each other and showed an analyte-speciﬁc frag-
mentation pattern as reported previously [13,21]. These offer ad-
vantages compared with other derivatives such as those formed
using dansyl chloride [11–16]; the product ion (m/z 110) re-
presenting the derivatization group for both steroids did not
dominate (Fig. 2).
Stable-isotopically labeled estrogens were used to elucidate
potential fragmentation pathways and the nature of both quanti-
ﬁer and qualiﬁer ions was proposed, based on a mechanism in-
cluding α–β cleavages, retro-Diels-Alder, methyl migration and
hydrogen shift (McLafferty þ1 reaction) [23] (Figs. 3 and 4). High
CID at 50 eV of the m/z 362 ion formed by E1-FMP generated two
product ions of signiﬁcant abundance at m/z 252 and 238. These
masses demonstrated an increment by þ2 to m/z 254 and 240 for
both d4-E1 and 13C2-E1, respectively, suggesting the presence of
the A ring in the fragment but loss of the steroidal D ring (with
2 deuteriums on C16). The formation of m/z 252 was proposed to
be a charge-remote concerted mechanism involving the elimina-
tion of CO as neutral loss before methyl migration from the 13C to
the C16 position in the steroid ring, followed by loss of [C6H10]þ via
a four-center concerted mechanism after α-cleavage of the C14-C15
bond. This may result in potential isomeric structures through the
double bond at C9. The product ion at m/z 238 was proposed to
form by loss of CH2 (as a radical cation) from C9, again creating two
possible isomeric structures. FTICR-MS analysis conﬁrmed the
structural formulae of the product ions of m/z 252.13821 and
238.12260 within 0.3 and 0.2 ppm of the theoretical masses
(252.13829 and 238.12264 amu; C17H18ON, C16H16ON structural
formulae, respectively). Similarly for 13C2-E1, masses of the pro-
duct ions (m/z 254.15090 and 240.13509) were within 0.2 and
0.4 ppm of the theoretical masses (254.15084 and 240.13519 amu;
13C2-C15H18ON, 13C2-C14H16ON structural formulae, respectively).
Conversely, CID experiments carried out at 55 eV on the FMP-
E2 precursor ion at m/z 364 generated two product ions of sig-
niﬁcant abundance but with lower mass, at m/z 128 and 110,
which underwent a mass increment to m/z 130 and 111, respec-
tively for d4-FMP-E2. 13C2-FMP-E2 in contrast generated product
ions of m/z 130 and 110. The product ion at m/z 110 was assumed
to originate from the derivatization tag, proposed to form by β-
cleavage of the ether bond at C4 followed by a proton migration via
a (four or six) center concerted mechanism from either C2 or C4 of
the steroid moiety. Therefore in analysis of d4-FMP-E2, an A-ring
deuterium may migrate, generating a product ion of m/z 111. In
contrast, the product ion at m/z 128 was proposed to form from
the steroid moiety, incorporating the A-ring (and hence two
deuteriums or two 13C atoms). The mechanism may be a charge-
remote concerted mechanism causing dehydration of the sec-
ondary alcohol at C17 with further β-cleavage of the ether bond at
C4 followed by a retro-Diels-Alder concerted mechanism, resulting
in two possible conjugated isomers. Due to the lower masses of
the product ions, further conﬁrmation could not be obtained by
FTICR-MS. The differences in behavior between the E1-FMP and
Fig. 2. Product ion scans of methylpyridinium ether derivatives of estrogens; (A) estrone (E1) (B) estradiol (E2) (C) 3,4-[13C]2-estrone (13C2E1) (D) 3,4-[13C]2-estradiol
(13C2E2) (E) 2,4,16,16-[2H]4-estrone (d4E1) (F) 2,4,16,16-[2H]4-estradiol (d4E2).
Fig. 3. Proposed fragmentation pattern of methylpyridinium ether derivatives of estrogens; (A) estrone (E1) (B) 3,4-[13C]2-estrone (13C2E1) (C) 2,4,16,16-[2H]4-estrone (d4E1).
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Fig. 4. Proposed fragmentation pattern of methylpyridinium ether derivatives of estrogens; (A) estradiol (E2) (B) 3,4-[13C]2-estradiol (13C2E2) (C) 2,4,16,16-[2H]4-estradiol
(d4E2).
A.M.M. Faqehi et al. / Talanta 151 (2016) 148–156 153E2-FMP fragmentation may relate to the unique stabilization of the
conjugated system of the E1 related fragment at m/z 252, after
ketone release and conformational rearrangement.
Accordingly, distinct quantiﬁer ions, derived from the steroidal
structure, were selected (Table 1) for E1 and E2 derivatives. Use of
m/z 128 as the quantiﬁer ion for E2- FMP, as opposed to m/z 110,
allowed distinction between analyte and A-ring isotopically-la-
beled estrogens, used either as internal standards or in vivo tra-
cers. Phase 1 metabolism of estrogens via oxidation occurs in the
A-ring, to form hydroxy and methoxy estrogens on the 2 and
4 positions [9]. Again this derivatization approach would offer
greater selectivity against unknown background interferences.
Three MS systems were used in this characterization. While they
were being applied for different purposes (high versus low con-
centration analysis and structural elucidation), the fact that the
same precursor and product ions could be detected in three MS
systems with different source conﬁgurations indicated a robust
method easily transferable between laboratories. Final tune con-
ditions in ESI mode for the FMP derivatives of estrogens, using the
quantiﬁer and qualiﬁer ions selected are shown in Table 1.
3.1.2. Optimization of derivatization reaction conditions
Reaction conditions to generate FMP derivatives were opti-
mized ﬁrst using aqueous extracts and then extracts of male and
female plasma and ﬁnal conditions reported. The efﬁciency of
reaction was improved by increasing temperature from 25 to 40°C
and time from 5 to 15 min, but further improvement was not seen
at higher temperatures or with longer incubations. Reassuringly
the intensity of signal was not adversely affected upon prolonged
incubation, proving robustness of the protocol within day-to-day
practice, but was improved by increasing the volume and con-
centration of FMP-TS from 25 to 50 mL and from 0.1 to 5 mg/mL,respectively
3.2. Chromatographic conditions
Baseline resolution between estrogen FMP derivatives within
reasonable analytical time was achieved using a C18 UHPLC col-
umn. Typical retention times for E1, E2 and 17αE2 were 4, 4.5 and
7.5 minutes, respectively (Fig. 5A). At early time points (until
2 minutes) the ﬂow was diverted to waste and towards the end of
the analysis where a rapid increasing organic gradient was used;
both strategies were employed to minimize build-up of derivati-
zation reagent on the column and in the source and were essential
for robustness during larger batch analysis.
3.3. Extraction
Previous methods to extract estrogens from biological matrices
had often employed solvent extraction, e.g. with methyl t-butyl
ether [20], and more recently, supported liquid extraction [10].
Following a thorough evaluation, the lipophilic polymeric ad-
sorbent, Oasiss, was ultimately selected for extraction of estrogens
[8,24–26]; this approach had been used successfully before in
monitoring of environmental estrogens. These cartridges showed
excellent retention of analytes, and generated a clean extract with
reproducible high recovery. Initial development using Oasiss HLB
[8, 22–24] showed excellent recoveries from water (mean7RSD;
E1 9974%, E2 9772%, 13C2E1 98710% and 13C2E2 9675%), but
signiﬁcant ion suppression was identiﬁed in the plasma extracts
(13C2E1 35%, 13C2E2 32% versus unextracted standards). Previous
problems with ion suppression of derivatized estrogens by phos-
pholipids have been reported [21] and were overcome with online
ion-exchange chromatography. Here suppression was minimized
Fig. 5. Mass chromatograms of quantiﬁer mass transitions of methylpyridinium ether (FMP) derivatives of estrogens; (A) chromatographic resolution of derivatives of
estrone (E1), estradiol (E2) and 17α-estradiol (17αE2) (400 pg) prepared from aqueous standard solutions. Derivatized E1 (B) and E2 (C) from standards prepared with
quantities equivalent to the limits of quantitation. Quantiﬁer mass transitions of 3,4-[13C]2 derivatized estrone (D,F) and 3,4-[13C]2 -estradiol (E,G) in standards (200 pg) and
blank plasma, respectively, demonstrating lack of interferences at the retention times of interest. Derivatized E1 (H, J), E2 (I, K) in extracts of female and male plasma,
respectively. Counts per second (cps).
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Table 2
Precision and accuracy of analysis of estrogens, measured as their methylpyr-
idinium derivatives.
Precision (%RSD) High (400 pg) Medium (50 pg) Low (1 pg)
Analyte E1 E2 E1 E2 E1 E2
Intra-assay 3 4 7 10 13 14
Inter-assay 5 6 9 15 15 16
Accuracy (%RME)
Intra-assay 12 13 12 15 18 17
Inter-assay 14 14 14 15 19 19
Estrone (E1) and estradiol (E2). Relative Standard Deviation (RSD) and Relative
Mean Error (RME).
Table 3
Concentrations of estrogens in males, pre- and post-menopausal females.
Group N Age (y) pg/mL Reference range
(pg/mL) [15,26]
E1 E2 E1 E2
Males 48 21–85 7–30 16–50 10–60 10–40
Pre-menopausal
females
27 24–52 36–128 52–196 17–200 15–350
Post-menopausal
females
20 58–60 6–21 8–14 7–40 o10
Estrone (E1) and estradiol (E2).
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ple; ultimately use of Oasiss MCX [27] extraction cartridges was
validated. Using this approach efﬁcient and consistent recovery of
estrogens from plasma was achieved for both analytes
(mean7RSD; E1 9575% and E2 9273%) and internal standards
(13C2E1 97712% and 13C2E 9076%), with minimum ion sup-
pression (post-spiked vs unextracted; 13C2 E1 9777%, 13C2 E2
9378%).
3.4. Assay validation
3.4.1. Speciﬁcity
Baseline chromatographic separation of estrogens (E1 and E2)
and endogenous isomers in plasma (17αE2) was achieved (Fig. 5A).
In plasma, the ratio of quantiﬁer to qualiﬁer mass transitions was
monitored by LC–MS/MS to ensure speciﬁcity (E11.1, E2 1.1, 13C2 E1
1.1 and 13C2 E2 1.4), comparable to those in aqueous solutions,
showing differences less than 20% (E1 10%, E2 0%, 13C2E1 8.3% and
13C2E2 17.6%). Interferences were not observed in plasma at the
retention times of the internal standards (Fig. 5D–G).
3.4.2. Linearity
13C2 labeled estrogens were selected as internal standards,
since loss of deuterium may happen during derivatization, parti-
cularly from the A-ring. At the outset of this work only estrogens
with two labeled carbons were available, but subsequently those
with three have become commercially available and may offer
enhanced mass distinction of isotopologues in future studies.
Linear standard curves of estrogen FMP derivatives were gener-
ated in the range (1–400 pg/sample) with a mean r value of
0.9953. Weighting of 1/x2 was applied, yielding a mean intercept
of 0.0017. This range is similar to that determined using other
sensitive derivatives developed recently [18].
3.4.3. Limits of detection and quantitation
The LOD and LOQs of FMP derivatives of both estrogens were
1 pg/sample (0.2 pg on column) (representative chromatograms
of LOQs shown in Fig. 5B and C). This could be achieved using
sample volumes of 0.5–2 mL, depending on subject characteristics.
This again compares favorably with other recent methods, e.g.
0.5 pg/mL [20], and is an improvement over previous reports using
dansyl chloride, albeit with older instrumentation [11]. The larger
sized Oasis cartridges were necessary to maintain a clean extract
when handling larger volume samples from post-menopausal
women.
3.4.4. Precision and accuracy
The values of intra- and inter-assay precision and accuracy were
acceptable (o20% RSD for precision and o720% accuracy) at the
LOQ of 1 pg/sample (Table 2) and o15% above this value. Acceptable
reproducibility of estrogens upon repeat injection of the same samplewas demonstrated with RSD; E1 (1%), E2 (4%) in male and E1 (9%) and
E2 (13%) in female plasma.
3.4.5. Stability
The FMP derivatives demonstrated suitable stability upon sto-
rage in an auto-sampler (10 °C) over 24 h, with limited degrada-
tion measured for derivatized E1 (7%, 5%) and E2 (9%, 6%) in ex-
tracts of samples from male and female subjects, respectively.
Derivatives were stable upon short-term storage in the freezer
(20 and 80°C, respectively) for 24 h; reduction from original
response E1 (2.5%, 1.1%), E2 (3.4%, 1.3%) in male and E1 (2.2%, 1.8%),
E2 (3.1%, 1.4%) in female. However, degradation of the derivative
was signiﬁcant after 48 h at 20°C; derivatized E1 (28%, 36%), E2
(29%, 42%) in male and female extracts, respectively. At 80°C,
stability of derivatives was acceptable after storage for 28 day;
reduction from original response for E1 (8%, 6%), E2 (9%, 8%) in
male and female plasma, respectively.
3.5. Method application
The method was applied to samples from pre- and post-me-
nopausal females and males and compared to reported biological
concentrations (Table 3). In clinical practice immunoassays are
used routinely to quantify estradiol, but not estrone, in serum from
pre-menopausal women [5,28]; the LC–MS/MS approach allowed
concomitant analysis of E2 and E1 across a wider age range and
may be extended to further metabolites.
In pre-menopausal female serum 0.5 mL of serumwas required
to ensure reliable detection throughout the menstrual cycle. In
males, E1 and E2 concentrations were quantiﬁed using 1 mL
plasma, whereas with plasma from post-menopausal female 2 mL
was required to ensure steroids were detected in all subjects.
Using these volumes, all concentrations fell within the quantita-
tion limits of the assay of (1–400 pg/sample) for E1 and E2 and
quantitiation was achieved within the range of the standard
curves.
These volumes and LOQs compared favorably with previous
literature. Volumes of serum or plasma from human and bovine in
previous MS methods [2,10,15–21] were 100–2000 mL with LOQs
0.1–32 pg on column. For example, Chang et al. [15] used 0.3–1 mL
of bovine plasma for simultaneous quantiﬁcation of E1 and E2,
while Yang et al. [19] used 2 mL of human serum to detect estro-
gens and their metabolites, with LOQs of 2 pg/on-column. Nel-
son et al. [16] and Xu et al. [17] reported lower LOQs (0.3 and
0.2 pg on column, respectively), again requiring between 0.5–
2 mL. Wooding achieved similar limits of detection using an ap-
proach without derivatisation, but could not robustly quantify
estrogens in all post-menopausal females sample tested [10].
Beinhauer et al. [21] has developed a method to trace estrogen
FMP derivatives with very low LOQ (0.7 pg on column) re-
covered from smaller volumes -100 mL human and bovine serum.
However, their approach utilized multiple injection loading with
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dansylated estrogens at even lower LOQs of 0.05–0.1 pg on col-
umn, utilizing only 200 mL human serum. However, this approach
required the use of 2-dimensional chromatographic separation;
again facilities for applying this technique are not commonly
available.4. Conclusions
In summary, derivatization to form FMP ethers of phenolic
estrogens, in conjunction with LC–MS/MS, is suitable for quanti-
tative analysis of E2 and E1 in low abundance in biological ﬂuids.
This approach allows robust measurement across typical physio-
logical ranges found in pre- and post-menopausal women and
men, contrasting favorably with immunoassays (for which im-
precise measurements are often recorded in the lower physiolo-
gical range of concentrations [19]). The improvements in sample
preparation allowed larger volumes to be processed without sig-
niﬁcant problems with ion suppression and the use of Oasis® MCX
cartridges will likely be compatible with other derivatisation
approaches.
Use of FMP-TS reagent offers improved speciﬁcity over pre-
viously reported derivatization approaches e.g. dansylation, but
care should be taken to store derivatized samples at 80 °C if not
being analysed within 24 h. Under these conditions all indices of
assay quality were acceptable. The derivatization reaction may be
applicable to other naturally occurring phenolic steroids.Acknowledgments
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